{
    "doi": "https://doi.org/10.1182/blood.V124.21.421.421",
    "start_url": "https://ashpublications.org/blood/search-results?sort=Date+-+Oldest+First&f_ArticleTypeDisplayName=Meeting+Report&fl_SiteID=1000001&page=2723",
    "start_url_page_num": 2723,
    "is_scraped": "1",
    "article_title": "Pre-Transplant Ferritin, Albumin and Platelet Count Add Prognostic Information to Comorbidities for Allogeneic Hematopoietic Cell Transplantation (HCT) Outcomes: A Multi-Center Discovery-Validation Study ",
    "article_date": "December 6, 2014",
    "session_type": "721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Transplant Toxicities: Personalizing Transplant Outcomes",
    "topics": [
        "albumins",
        "comorbidity",
        "ferritin",
        "hematopoietic stem cell transplantation",
        "platelet count measurement",
        "transplantation",
        "biological markers",
        "allogeneic hematopoietic stem cell transplant",
        "hemoglobin",
        "allogeneic stem cell transplant"
    ],
    "author_names": [
        "Jennifer E. Vaughn, MD MSPH",
        "Barry E. Storer, PhD",
        "Philippe Armand, MD PhD",
        "Roberto Raimondi, MD",
        "Christopher J Gibson, MD",
        "Alessandro Rambaldi, MD",
        "Fabio Ciceri, MD",
        "Rosi Oneto, MD",
        "Benedetto Bruno, MD PhD",
        "Paul J. Martin, MD",
        "Brenda M. Sandmaier, MD",
        "Rainer F. Storb, MD",
        "Mohamed L. Sorror, MD MSc"
    ],
    "author_affiliations": [
        [
            "Fred Hutchinson Cancer Research Center, Seattle, WA ",
            "University of Washington, Seattle, WA "
        ],
        [
            "Fred Hutchinson Cancer Research Center, Seattle, WA ",
            "University of Washington School of Public Health, Seattle, WA "
        ],
        [
            "Dana-Farber Cancer Institute, Boston, MA "
        ],
        [
            "Ospedale San Bortolo, Vicenza, Italy "
        ],
        [
            "Dana-Farber Cancer Institute, Boston, MA "
        ],
        [
            "Ospedali Riuniti Bergamo, Bergamo, Italy "
        ],
        [
            "San Raffaele Scientific Institute, Milano, Italy "
        ],
        [
            "Ospedale San Martino, Genova, Italy "
        ],
        [
            "University of Torino, A.O.U. San Giovanni Battista, Torino, Italy "
        ],
        [
            "Fred Hutchinson Cancer Research Center, Seattle, WA ",
            "University of Washington, Seattle, WA "
        ],
        [
            "Fred Hutchinson Cancer Research Center, Seattle, WA ",
            "University of Washington, Seattle, WA "
        ],
        [
            "University of Washington School of Medicine, Seattle, WA ",
            "Fred Hutchinson Cancer Research Center, Seattle, WA"
        ],
        [
            "Fred Hutchinson Cancer Research Center, Seattle, WA ",
            "University of Washington, Seattle, WA "
        ]
    ],
    "first_author_latitude": "47.626835199999995",
    "first_author_longitude": "-122.3314659",
    "abstract_text": "Albumin, ferritin, and peripheral blood counts broadly capture health status in patients undergoing allogeneic stem cell transplantation (HCT). Whether they add any prognostic information to the HCT-Comorbidity Index (HCT-CI) is unknown. We analyzed the independent prognostic role of a group of 5 biomarkers (ferritin, albumin, absolute neutrophil count (ANC), hemoglobin (Hgb), and platelet (Plt) count) in pts given allogeneic HCT for hematologic malignancies. This was a multi-center, retrospective discovery-validation study comprising data from 3917 recipients of allogeneic HCT at the Fred Hutchinson Cancer Research Institute (FHCRC) (n=1789) and Dana Farber Cancer Institute (DF) (n=716) in the US and the Gruppo Italiano Trapianto di Midollo Osseo (GITMO) (n=1412) in Italy (Table 1). Proportional hazard models were used to estimate the hazards of non-relapse mortality (NRM) and survival after adjustment for the HCT-CI, donor type, CMV serostatus, regimen intensity, age, disease risk and Karnofsky Performance Status (KPS). These were stratified by institution. Model performances were tested by c-statistic estimates. In an initial analysis within the FHCRC population, ANC of 1000 (HR 1.98; p=0.0003) and >2500 (HR 1.97; p=0.0005); albumin <3.5 (HR 1.63; p<0.00001) and <3.0 (HR 1.73 p<0.0001); and Plt <100k (HR 1.65; p<0.0001), <50k (HR 1.52; p<0.0001) , and <20K (HR 1.54; p<0.008) were all statistically significantly associated with NRM. Results were validated in a larger population from DF and GITMO. In multivariate models, adjusted for previously mentioned variables, ferritin >2500 and incremental decreases in albumin and Plt counts had statistically significant associations with both NRM and survival (Table 2). Of note, HCT-CI scores (2, 3 and >4) also retained significant associations with NRM and survival in the presence of the three biomarker values and in both cohorts. Subsequent multivariate analyses stratified the whole cohort (n=3917) into a training (n=2352) and a validation (n=1407) set. In both sets, albumin 2500 had statistical significance associations with NRM and survival. Each of the three biomarker values were subsequently assigned a weight of 1 following the same equation used to develop the HCT-CI. The augmented HCT-CI/biomarker index had higher c-statistic estimate (0.61) for prediction of NRM compared to the HCT-CI alone (0.58) in the validation set. Ferritin, albumin, and Plt counts are simple and valid prognostic biomarkers for transplant outcomes and should be considered in combination with the HCT-CI in risk assessment prior to allogeneic HCT. The physiology behind these associations warrants further investigation to identify areas of intervention that may improve outcomes. Table 1: Pt characteristics  . FHCRC (N=1789) . DF/GITMO (N=2128) . . N (%) . N (%) . Donor   Related 900 (50) 1062 (50) Unrelated 889 (50) 1053 (50) Disease risk   Low 740 (41) 866 (43) High 1049 (59) 1157 (57) Age   < 50 1025 (57) 1120 (53) \u2265 50 764 (43) 1008 (47) Conditioning   MA 983 (55) 1100 (52) RIC/NMA 806 (45) 1004 (48) Pt CMV   - 773 (43) 505 (24) + 1016 (57) 1581 (76) KPS   \u2264 90 691 (39) 644 (33) 90-100 1098 (61) 1304 (67) . FHCRC (N=1789) . DF/GITMO (N=2128) . . N (%) . N (%) . Donor   Related 900 (50) 1062 (50) Unrelated 889 (50) 1053 (50) Disease risk   Low 740 (41) 866 (43) High 1049 (59) 1157 (57) Age   < 50 1025 (57) 1120 (53) \u2265 50 764 (43) 1008 (47) Conditioning   MA 983 (55) 1100 (52) RIC/NMA 806 (45) 1004 (48) Pt CMV   - 773 (43) 505 (24) + 1016 (57) 1581 (76) KPS   \u2264 90 691 (39) 644 (33) 90-100 1098 (61) 1304 (67) View Large Table 2: Multivariate analysis showing the associations between biomarkers and NRM and survival.  . . NRM . Survival . Marker  HR 1  P 1  HR 1  P 1  FHCRC Albumin \u22653.5 1.0  1.0   <3.5 - 3.0 1.44 0.002 1.45 <0.0001  <3.0 1.77 <0.0001 1.77 <0.0001  Unk 1.15 0.38 1.19 0.11 Plts \u2265100K 1.0  1.0   <100K \u2013 50K 1.48 0.0007 1.28 0.003  <50K \u2013 20K 1.49 0.003 1.37 0.001  <20K 1.64 0.005 1.58 0.0004  Unk 0.66 0.47 0.48 0.14 Ferritin \u22641000 1.0  1.0   >1000 - 2500 1.60 0.03 1.70 0.0006  >2500 2.08 0.001 1.63 0.007  Unk 1.42 0.03 1.44 0.002 HCT-CI 0 1.0  1.0   1 1.29 0.12 1.31 0.02  2 1.50 0.01 1.42 0.001  3 2.29 <0.0001 2.04 <0.0001  \u2265 4 2.94 <0.0001 2.42 <0.0001 DF/GITMO Albumin \u22653.5 1.0  1.0   <3.5 - 3.0 1.60 0.0001 1.36 0.0005  <3.0 2.77 <0.0001 2.18 <0.0001  Unk 1.61 0.01 1.11 0.49 Plts \u2265100K 1.0  1.0   <100K \u2013 50K 1.08 0.56 1.02 0.85  <50K \u2013 20K 1.17 0.28 1.21 0.06  <20K 1.38 0.04 1.35 0.009  Unk 0.64 0.10 0.82 0.28 Ferritin \u22641000 1.0  1.0   >1000 - 2500 1.11 0.43 1.23 0.02  >2500 1.60 0.002 1.69 <0.0001  Unk 1.13 0.33 1.12 0.19 HCT-CI 0 1.0  1.0   1 1.31 0.05 1.14 0.19  2 1.29 0.10 1.25 0.04  3 1.48 0.006 1.46 0.0001  \u2265 4 1.74 <0.0001 1.66 <0.0001 . . NRM . Survival . Marker  HR 1  P 1  HR 1  P 1  FHCRC Albumin \u22653.5 1.0  1.0   <3.5 - 3.0 1.44 0.002 1.45 <0.0001  <3.0 1.77 <0.0001 1.77 <0.0001  Unk 1.15 0.38 1.19 0.11 Plts \u2265100K 1.0  1.0   <100K \u2013 50K 1.48 0.0007 1.28 0.003  <50K \u2013 20K 1.49 0.003 1.37 0.001  <20K 1.64 0.005 1.58 0.0004  Unk 0.66 0.47 0.48 0.14 Ferritin \u22641000 1.0  1.0   >1000 - 2500 1.60 0.03 1.70 0.0006  >2500 2.08 0.001 1.63 0.007  Unk 1.42 0.03 1.44 0.002 HCT-CI 0 1.0  1.0   1 1.29 0.12 1.31 0.02  2 1.50 0.01 1.42 0.001  3 2.29 <0.0001 2.04 <0.0001  \u2265 4 2.94 <0.0001 2.42 <0.0001 DF/GITMO Albumin \u22653.5 1.0  1.0   <3.5 - 3.0 1.60 0.0001 1.36 0.0005  <3.0 2.77 <0.0001 2.18 <0.0001  Unk 1.61 0.01 1.11 0.49 Plts \u2265100K 1.0  1.0   <100K \u2013 50K 1.08 0.56 1.02 0.85  <50K \u2013 20K 1.17 0.28 1.21 0.06  <20K 1.38 0.04 1.35 0.009  Unk 0.64 0.10 0.82 0.28 Ferritin \u22641000 1.0  1.0   >1000 - 2500 1.11 0.43 1.23 0.02  >2500 1.60 0.002 1.69 <0.0001  Unk 1.13 0.33 1.12 0.19 HCT-CI 0 1.0  1.0   1 1.31 0.05 1.14 0.19  2 1.29 0.10 1.25 0.04  3 1.48 0.006 1.46 0.0001  \u2265 4 1.74 <0.0001 1.66 <0.0001 1 Adjusted for donor , CMV serostatus , regimen intensity , age , disease risk , KPS ; stratified on institution. Unk=Unknown View Large Disclosures No relevant conflicts of interest to declare."
}